Medtronic, Inc.

710 Medtronic Pkwy
Minneapolis, MN 55432-5604
USA
Phone:
763-514-4000
Fax:
763-514-4879
www.medtronic.com

Medtronic is the world leader in medical technology providing lifelong solutions for people with chronic disease. We offer products, therapies and services that enhance or extend the lives of millions of people. Each year, 5 million patients benefit from Medtronic's technology, used to treat conditions such as diabetes, heart disease, neurological disorders, and vascular illnesses.

Related Content

The FDA cleared the IN.PACT AV drug-coated Balloon. Clinical data shows In.Pact AV DCB is Safe, reduces reinterventions and maintains access for end-stage renal disease patients undergoing dialysis
News | November 26, 2019
FDA Clears Medtronic Drug-Coated Balloon to Treat Arteriovenous Fistula Lesions
The U.S. Food and Drug Administration (FDA) has cleared the Medtronic In.Pact AV drug-coated balloon (DCB) for the...
read more
Results from the MARVEL 2 (Micra Atrial Tracking Using A Ventricular accELerometer) study shows that an investigational set of algorithms in the Medtronic Micra Transcatheter Pacing System (TPS) significantly improves synchrony and cardiac function in patients with atrioventricular (AV) block. This is an impaired electrical conduction between the chambers of the heart.
News | Pacemakers | November 15, 2019
New Algorithms in Medtronic Micra Pacemaker May Improve Synchrony and Cardiac Function in AV Block
November 15, 2019 — Results from the MARVEL 2 (Micra Atrial Tracking Using A Ventricular accELerometer) study shows t
read more
The IN.PACT Arteriovenous (AV) Access randomized trial evaluating the safety and effectiveness of the Medtronic IN.PACT AV Access drug-coated balloon (DCB) met both of its endpoints, in data presented at the 2019 Vascular Interventional Advances (VIVA) annual meeting. #VIVA #VIVA19 #VIVA2019

The IN.PACT Arteriovenous (AV) Access randomized trial evaluating the safety and effectiveness of the Medtronic IN.PACT AV Access drug-coated balloon (DCB) met both of its endpoints, in data presented at the 2019 Vascular Interventional Advances (VIVA) annual meeting.

 

News | Drug-Eluting Balloons | November 14, 2019
IN.PACT AV Access 6-Month Data Show Increased Vessel Patency
November 7, 2019 — The IN.PACT Arteriovenous (AV) Access randomized trial evaluating the safety and effectiveness of
read more
In.Pact Admiral drug-coated balloon (DCB). #VIVA #VIVA19 #VIVA2019

The In.Pact Admiral drug-coated balloon.

News | Drug-Eluting Balloons | November 07, 2019
Drug-coated Balloon Maintains Good Outcomes in 4-Year IN.PACT Global Study Data
November 7, 2019 — Real-world, four-year study results of the In.Pact Admiral drug-coated balloon (DCB) demonstrate l
read more
Medtronic Initiates Worldwide Pivotal Study of Extravascular Implantable Cardioverter Defibrillator
News | Implantable Cardioverter Defibrillator (ICD) | October 11, 2019
Medtronic Initiates Worldwide Pivotal Study of Extravascular Implantable Cardioverter Defibrillator
Medtronic plc announced the start of a worldwide pivotal study evaluating its investigational Extravascular Implantable...
read more
FDA Grants Breakthrough Device Designation for Valiant Thoracoabdominal Aortic Aneurysm Stent Graft
News | Stent Grafts | October 09, 2019
FDA Grants Breakthrough Device Designation for Valiant Thoracoabdominal Aortic Aneurysm Stent Graft
Medtronic plc announced it has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA...
read more
Medtronic is recalling the 6 French Sherpa NX Active Guide Catheter due to a risk of the outer material separating from the device resulting in detached fragments that could result in the underlying stainless-steel braid wires being exposed. These fragments could be left inside the patient’s bloodstream, and this or the attempts made to retrieve the fractured pieces, can cause other serious adverse health consequences such as continued blockage of blood vessels, injury to blood vessel walls, development of
News | October 09, 2019
Medtronic Recalls 6 French Sherpa NX Active Guide Catheters
October 9, 2019 — Medtronic is recalling the 6 French Sherpa NX Active Guide Catheter due to a risk of the outer mate
read more
Medtronic Launches Evolut Pro+ TAVR System
Technology | Heart Valve Technology | September 24, 2019
Medtronic Launches Evolut Pro+ TAVR System
Medtronic announced U.S. Food and Drug Administration (FDA) approval and U.S. launch of the Evolut Pro+ transcatheter...
read more
FDA Approves Sapien 3, CoreValve Evolut TAVR Valves for Low-risk Patients

Left, an illustration of the beginning of deployment for a CoreValve Evolut self-expanding transcatheter aortic replacement (TAVR) valve. Right, an illustration of the final balloon expansion of an Edwards Lifesciences Sapien 3 TAVR valve. Both valves received simultaneous FDA clearance for use in low-risk surgical patients. Clearing this last hurdle now allows wide-spread use of minimally invasive TAVR in all patients who otherwise would need an open-heart surgical valve replacement. 

Feature | Heart Valve Technology | August 16, 2019 | Jeff Zagoudis, Associate Editor, and Dave Fornell, Editor
FDA Approves TAVR for Low-risk Patients Creates A Paradigm Shift in Cardiology
In one coordinated move, the U.S. Food and Drug Administration (FDA) opened transcatheter aortic valve replacement (...
read more
A physician explaining an implantable cardioverter defibrillator (ICD) to a patient. Image courtesy of Biotronik.

A physician explaining an implantable cardioverter defibrillator (ICD) to a patient. Image courtesy of Biotronik.

Feature | Implantable Cardioverter Defibrillator (ICD) | May 24, 2019 | Dave Fornell, Editor
New Technology and Market Challenges Facing Implantable Cardioverter Defibrillators
This is a brief overview of updates on...
read more
© Copyright Scranton Gillette Communications. All Rights Reserved.
Overlay Init